Clinical and Life Sciences · 30 September 2026 to 30 September 2026 · 1 headlines · STAT

STAT Plus: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial

Eli Lilly's Zepbound, combined with an amylin drug, led to significant weight loss in a mid-stage clinical trial.

As it ran

30 September 2026

STAT Plus: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial STAT

More from US healthcare

STAT Plus: Three biotech updates, including accusations of theft and and a new lobbying leader 30 September 2026
STAT Plus: At MAHA Summit, a grassroots movement goes corporate 30 September 2026
America’s biotech race with China must be won at home 30 September 2026
CAR-T Therapy Shows Durable Benefits in Myasthenia Gravis 30 September 2026
Drugs Are Widely Used To Sedate Dementia Patients. Her Sons Wanted To Keep Her Off Them. 30 September 2026
HOPDs' higher drug payment rates drive $12.7B in spending: EBRI 30 September 2026
T cell brain barrier research 30 September 2026
Vaccine and drug policy in the midterm elections 29 September 2026